OncoMatch/Clinical Trials/NCT06923826
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
Is NCT06923826 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sacituzumab govitecan for salivary gland cancer.
Treatment: Sacituzumab govitecan — The goal of this clinical trial is to learn if the drug, sacituzumab govitecan, works to treat: 1. Salivary gland cancers that have spread to other parts of the body or come back after previous treatment, and cannot be removed by surgery 2. A type of thyroid cancer (specifically, differentiated thyroid carcinoma) that has spread to other parts of the body or come back after previous treatment, no longer responds to radioactive iodine treatment and cannot be removed by surgery The main question it aims to answer is whether sacituzumab govitecan can treat the 2 conditions mentioned above in a safe and effective manner. Participants will: * Receive sacituzumab govitecan by intravenous (IV) infusion on Day 1 and Day 8 of each treatment cycle. Each treatment cycle is 21 days (3 weeks) long. * Visit the clinic before each infusion for checkups and blood tests * Go through CT/PET/MRI scan once every 6 weeks for the first 24 weeks, then every 9 weeks thereafter. * Go through 2 tumour biopsies (if assessed by the doctor to be safe) at the start and at the end of study participation Participants will continue to receive treatment with sacituzumab govitecan until their cancer stops responding to the drug or if they decide to withdraw from the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Thyroid Cancer
Biomarker criteria
Allowed: RET somatic pathogenic alteration
if known to harbour somatic pathogenic RET alteration ... must have received 2 prior lines of TKIs
Allowed: NTRK1 gene fusion
if known to harbour ... NTRK gene fusion ... must have received 2 prior lines of TKIs
Allowed: NTRK2 gene fusion
if known to harbour ... NTRK gene fusion ... must have received 2 prior lines of TKIs
Allowed: NTRK3 gene fusion
if known to harbour ... NTRK gene fusion ... must have received 2 prior lines of TKIs
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic treatment — salivary gland cancer
Patients with metastatic or recurrent unresectable advanced salivary gland cancers must have progressive disease within the previous 6 months and have seen at least 1 prior line of systemic treatment, unless ... contraindications ... or there was no standard of care for that particular salivary gland histological subtype
Must have received: tyrosine kinase inhibitor — RAI refractory differentiated thyroid carcinoma
Patients with unresectable metastatic or recurrent RAI refractory differentiated thyroid carcinoma, must have progressive disease within the previous 13 months and have seen at least 1 prior line of tyrosine kinase inhibitor (TKI), unless ... contraindications to the TKIs
Cannot have received: radiation therapy
Exception: must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
Has received prior radiotherapy within 2 weeks of the start of study treatment
Cannot have received: investigational agent
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to first dose of study treatment
Cannot have received: live virus vaccination
History of having received a live virus vaccination (e.g., yellow fever, MMR, nasal flu, chicken pox or Zostavax) within 4 weeks prior to the first dose of trial treatment
Lab requirements
Blood counts
adequate organ function (details not specified)
Kidney function
adequate organ function (details not specified)
Liver function
adequate organ function (details not specified)
Have an adequate organ function. Specimens must be collected within 10 days prior to the start of study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify